Applying PCSK9 Inhibitors to Optimize Outcomes in Patients with Dyslipidemia

The content for this activity is derived from a live symposium titled, “Applying PCSK9 Inhibitors to Optimize Outcomes in Patients With Dyslipidemia” presented at the American Heart Association Scientific Sessions 2017 in Anaheim, California. This CME activity will highlight optimal treatment and management strategies for patients with dyslipidemia in the era of PCSK9 inhibitors. The expert faculty will review recent clinical trial and CVD outcomes data, encompassing lipid lowering therapies for the diabetic patient subset. Dyslipidemia guidelines as well as strategies for achieving LDL-C goal will be outlined, particularly in the high-risk population. Dr. Christopher P. Cannon and the accompanying faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision making. This CME program will provide cardiologists with vital information for improving healthcare outcomes in patients with dyslipidemia.


This activity has been designed to meet the educational needs of cardiologists and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.


Upon completion of this activity, participants will be better able to do the following:

  1. Identify the current dyslipidemia guidelines and consensus statements to achieve LDL-C goal
  2. Compare available pharmacotherapies that reduce LDL-C
  3. Analyze the details of the CVD outcomes trial data for patients on PCSK9 inhibitors, including the diabetic patient subset
  4. Prioritize the most current treatment plans for patients with familial hypercholesterolemia
  5. Apply current algorithms and treatment models for managing the high-risk patient with dyslipidemia


Christopher P. Cannon, MD (Program Chair)
Professor of Medicine
Harvard Medical School
Executive Director of Cardiometabolic Trials
Baim Institute for Clinical Research
Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts

Christie M. Ballantyne, MD
Professor of Medicine
Vice-Chair of Research-Department of Medicine
Chief-Section of Cardiology
Chief-Section of Cardiovascular Research
Baylor College of Medicine
Houston, Texas
Alan S. Brown, MD
Director, Division of Cardiology
Advocate Lutheran General Hospital
President-Elect, National Lipid Association
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch Medical School
Park Ridge, Illinois
Robert H. Eckel, MD
Professor of Medicine
Division of Endocrinology, Metabolism, and Diabetes, and Cardiology
Charles A. Boettcher II Chair in Atherosclerosis
University of Colorado
Anschutz Medical Campus
Aurora, Colorado
Robert P. Giugliano, MD, SM
Associate Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women's Hospital
Boston, Massachusetts
James A. Underberg, MD, MS
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, New York

Disclosure of Conflicts of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this inter professional educational activity:
FacultyRelationship Identified With:
Christopher P. Cannon, MD
Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Amgen Inc.; Amarin Corporation; Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eisai Co., Ltd.; GlaxoSmithKline Plc; Kowa; LipoMedix; Merck & Co., Inc.; Pfizer Inc.; Regeneron; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support: Amgen Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Janssen Global Services, LLC; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.

Christie M. Ballantyne, MD

Consultant/Advisor: Abbott Diagnostics; Amarin Corporation; Amgen Inc.; AstraZeneca; Boehringer Ingelheim; Eli Lilly and Company; Ionis Pharmaceuticals, Inc.; Matinas BioPharma Holdings Inc.; Merck & Co., Inc.; Novartis Global; Pfizer Inc.; Regeneron; Roche Diagnostics; Sanofi
Grant/Research Support: Abbott Diagnostics; Amarin Corporation; Amgen Inc.; Esperion; Ionis Pharmaceuticals, Inc.; Novartis Global; Pfizer Inc.; Regeneron; Roche Diagnostics; Sanofi

Alan S. Brown, MD

Consultant/Advisor: Akcea Therapeutics; Amgen Inc.; Kastle Therapeutics; Kowa; Merck & Co., Inc.; Regeneron
Speaker's Bureau: Amgen Inc.; Kowa; Regeneron; Sanofi

Robert H. Eckel, MD

Consultant/Advisor: Regeneron; Sanofi

Robert P. Giugliano, MD, SM

Consultant/Advisor: Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVS Caremark; Daiichi Sankyo Company Limited; GlaxoSmithKline Plc; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Portola Pharmaceuticals, Inc.; Pfizer Inc.; Stealth BioTherapeutics Incorporated
Grant/Research Support: Amgen Inc.
Speakers Bureau: Amgen Inc.; Daiichi Sankyo Company Limited; Merck & Co., Inc.

James A. Underberg, MD, MS

Consultant/Advisor: Gilead; Proteostasis Therapeutics, Inc.; Vertex Pharmaceuticals Incorporated
Consultant/Advisor: Aegerion Pharmaceuticals Inc; Akcea Therapeutics; Alexion Pharmaceuticals; Amarin Corporation; Amgen Inc.; Invitae Corporation; Regeneron; Sanofi
Grant/Research Support: Aegerion Pharmaceuticals Inc; Pfizer Inc.
Speakers Bureau: Alexion Pharmaceuticals; Amarin Corporation; Amgen Inc.; Regeneron; Sanofi; True Health Group LLC

Non-faculty: Timothy Hayes, MD, PhD; Emma Boring, Nicole Brestowski and Chelsey Benedek hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Provider Information

This activity is provided by AcademicCME.

Credit Designation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact please contact or 610.687.3300.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Non-physician

Accreditation Period

Course opens: 
Course expires: 
Please login or register to take this course.